Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Immunex Preparing Enbrel Infection Risk Study And BLA For RA Progression

  • News

Executive Summary

Immunex has agreed to perform large, prospectively defined studies to assess the risk of serious infection related to use of its rheumatoid arthritis therapy Enbrel (etanercept) following reports of sepsis and death with the product.

You may also be interested in...



Remicade RA Therapy Meets Medicare Criteria For Infused Drug - Centocor

Centocor has been communicating with the Health Care Financing Administration regarding Medicare coverage for the newly approved rheumatoid arthritis indication for Remicade.

Remicade RA Therapy Meets Medicare Criteria For Infused Drug - Centocor

Centocor has been communicating with the Health Care Financing Administration regarding Medicare coverage for the newly approved rheumatoid arthritis indication for Remicade.

AHP Enbrel Market Expansion Plans Include Up To 2.4 Mil. U.S. Patients

The next step in Wyeth-Ayerst's plans to expand the market for Enbrel will be the presentation of the pivotal trial data in early rheumatoid arthritis during the upcoming American College of Rheumatology conference in Boston, Nov. 13-17.

Table

View full table

Tags:
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS034171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By